Aim: To investigate the expression of human kallikrein 15 (KLK15) in the primary epithelial ovarian carcinoma and the clinical significance.
目的：研究上皮性卵巢癌组织中人类组织激肽释放酶15 (KLK15)蛋白的表达。
On the cell of expressing human tissue kallikrein for gene modification, rigid envelope material with bi-directional flowability is coated.
在基因修饰的表达人组织激肽释放酶的细胞上包覆着具有刚性和双向流通性的包膜材料；
CONCLUSION Human urinary kallikrein is effective and relatively safe in treatment of acute cerebral infarction in the vascular distribution of the internal carotid artery.
结论人尿激肽原酶治疗急性颈内动脉系统脑梗死所致的神经功能缺损，其效果及安全性良好。
The present invention relates to human tissue kallikrein, and is especially the microcapsulized cell of human tissue kallikrein and its microcapsulizing method and application.
本发明涉及人组织激肽释放酶，具体地说是人组织激肽释放酶的微囊化细胞及其微囊化方法和应用；
The invention relates to the pharmaceutical use of human urinary kallikrein in the treatment of acute coronary artery disease and pharmaceutical composition prepared by the method.
本发明涉及人尿激肽原酶用于治疗急性冠状动脉疾病的药物用途及按该方法制备的药物组合物。
The invention relates to the pharmaceutical use of human urinary kallikrein in the treatment of acute coronary artery disease and pharmaceutical composition prepared by the method.
本发明涉及人尿激肽原酶用于治疗急性冠状动脉疾病的药物用途及按该方法制备的药物组合物。
应用推荐